QSAR and 3D-QSAR of phenothiazine type multidrug resistance modulators in P388/ADR cells

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 13, 2003, Pages 2889-2899

  Tsakovska, Ivanka M ^a  

^a CENTRE OF BIOMEDICAL ENGINEERING   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ACEPROMAZINE; ACEPROMETAZINE; ACETOPHENAZINE; AHR 06601; BUTAPERAZINE; CARFENAZINE; CHLORPROMAZINE; CLOPENTHIXOL; DOXORUBICIN; DUOPERONE; FLUPENTIXOL; FLUPHENAZINE; HYDROGEN; IMIPRAMINE; PERAZINE; PERPHENAZINE; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVE; PIPERACETAZINE; PROCHLORPERAZINE; PROMAZINE; PROMETHAZINE; PROTHIPENDYL; THIOPROPERAZINE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; TRIMIPRAMINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CELL LINE; CHEMICAL STRUCTURE; DRUG ACTIVITY; DRUG EFFECT; HYDROGEN BOND; HYDROPHOBICITY; LEUKEMIA CELL; MOLECULAR BIOLOGY; MOLECULAR MODEL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PREDICTION; PROTON TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY;

MURINAE;

EID: 0038548049     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00222-0     Document Type: Article

References (25)

1. Gottesman M., Pastan I. Annu. Rev. Biochem. 62:1993;385.
2. Safa, A. In: Methods in Enzymology; Ambudkar, S.; Gottesman, M., Ed.;. Academic: San Diego, 1998; Vol. 292, pp. 289-307.
3. Ford J., Hait W.N. Pharmacol. Rev. 42:1990;155.
4. Kellen J. Anticancer Res. 13:1993;959.
5. Ford J.M. Hematol./Oncol. Clin. North Am. 9:1995;337.
6. Ambudkar S., Dey S., Hrycyna C., Ramachandra M., Pastan I., Gottesman M. Annu. Rev. Pharmacol. Toxicol. 39:1999;361.
7. Ahkmed N., Fojo A.T., Bates S.E., Scala S. Proc. Am. Assoc. Cancer Res. 36:1995;339.
8. Chiba P., Ecker G., Schmid D., Drach J., Tell B., Goldenberg S., Gekeler V. Mol. Pharmacol. 49:1996;1122.
9. Ford J.M., Prozialeck W.C., Heit W.N. Mol. Pharmacol. 35:1989;105.
10. Ford J.M., Briggeman E.P., Pastan I., Gottesman M., Hait W.N. Cancer Res. 50:1990;1748.
11. Ramu, A. In: Resistance to Antineoplastic Drugs; Kessel, D., Ed., CRC: Boca Raton, Florida, 1989, pp 63-80.
12. Ramu A., Ramu N. Cancer Chemother. Pharmacol. 30:1992;165.
13. Pajeva I., Wiese M. Quant. Struct.-Act. Relat. 16:1997;1.
14. Pajeva I., Wiese M. J. Med. Chem. 41:1998;1815.
15. Pajeva I., Wiese M. Quant. Struct.-Act. Relat. 18:1999;369.
16. Tmej C., Chiba P., Huber M., Richter E., Hitzler M., Schaper K.-J., Ecker G. Arch. Pharm. Pharm. Med. Chem. 331:1998;233.
17. Kim K. Bioorg. Med. Chem. 9:2001;1517.
18. Ecker G., Huber M., Schmied D., Chiba P. Mol. Pharmacol. 56:1999;791.
19. Higgins C.F. Cell. 79:1994;393.
20. Stein W.D. Physiol. Rev. 77:1997;545.
21. Schmid D., Ecker G., Kopp S., Hitzler M., Chiba P. Biochem. Pharmacol. 58:1999;1447.
22. Kubinyi, H. In: Comprehensive Medicinal Chemistry; Sammes, P.; Taylor, J., Ed.; Pergamon Press: Oxford, 1990; Vol. 21, pp 593-610.
23. Tripos Inc., 1699 Hanley Road, St. Louis, MO 63144, USA.
24. Klebe, G. In: 3D-QSAR in Drug Design. Recent Advances; Kubinyi, H.; Folkers, G.; Martin, Y., Ed.; Kluwer/ESCOM: Dordrecht, 1998; Vol 3, pp 87-104.
25. Advanced Chemistry Development Inc., 90 Adelaide Street West, Suite 702, Toronto, Ontario M5H 3V9, Canada.